IRIS
PORTA, Camillo Guglielmo Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.198
AS - Asia 5.843
EU - Europa 5.372
SA - Sud America 2.364
Continente sconosciuto - Info sul continente non disponibili 1.598
AF - Africa 268
OC - Oceania 9
Totale 26.652
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.609
IT - Italia 2.429
SG - Singapore 2.268
BR - Brasile 1.808
HK - Hong Kong 868
CN - Cina 711
VN - Vietnam 689
FR - Francia 503
RU - Federazione Russa 445
SE - Svezia 432
FI - Finlandia 415
DE - Germania 357
GB - Regno Unito 301
CA - Canada 244
ID - Indonesia 233
BD - Bangladesh 220
AR - Argentina 205
IN - India 163
EC - Ecuador 107
IQ - Iraq 93
TR - Turchia 93
MX - Messico 81
CO - Colombia 79
JP - Giappone 77
AT - Austria 75
NL - Olanda 74
ZA - Sudafrica 70
PK - Pakistan 69
ES - Italia 59
SA - Arabia Saudita 57
VE - Venezuela 54
IE - Irlanda 52
PH - Filippine 50
CI - Costa d'Avorio 47
MA - Marocco 41
PL - Polonia 40
UZ - Uzbekistan 39
PY - Paraguay 37
CR - Costa Rica 35
JM - Giamaica 34
CL - Cile 29
SV - El Salvador 28
HN - Honduras 27
TT - Trinidad e Tobago 27
NI - Nicaragua 24
UA - Ucraina 22
JO - Giordania 21
PR - Porto Rico 21
GT - Guatemala 20
KE - Kenya 20
MY - Malesia 20
AL - Albania 19
AZ - Azerbaigian 19
BE - Belgio 18
EG - Egitto 18
LT - Lituania 18
NP - Nepal 18
PE - Perù 17
TN - Tunisia 17
AE - Emirati Arabi Uniti 14
CW - ???statistics.table.value.countryCode.CW??? 13
CZ - Repubblica Ceca 13
DO - Repubblica Dominicana 13
IL - Israele 13
UY - Uruguay 13
BO - Bolivia 11
ET - Etiopia 11
TH - Thailandia 11
RO - Romania 10
CH - Svizzera 9
KZ - Kazakistan 9
OM - Oman 9
PT - Portogallo 9
AU - Australia 8
BH - Bahrain 8
DZ - Algeria 8
KR - Corea 8
RS - Serbia 8
EE - Estonia 7
MK - Macedonia 7
PS - Palestinian Territory 7
BG - Bulgaria 6
GP - Guadalupe 6
KG - Kirghizistan 6
LB - Libano 6
PA - Panama 6
QA - Qatar 6
SN - Senegal 6
SY - Repubblica araba siriana 6
AO - Angola 5
BB - Barbados 5
BS - Bahamas 5
DK - Danimarca 5
TW - Taiwan 5
AM - Armenia 4
BY - Bielorussia 4
HR - Croazia 4
HU - Ungheria 4
LU - Lussemburgo 4
BA - Bosnia-Erzegovina 3
Totale 24.981
Salva come PNG Salva come JPEG
Città #
Ashburn 1.257
Singapore 1.195
San Jose 1.129
Milan 849
Hong Kong 847
Fairfield 649
Council Bluffs 520
Helsinki 400
Cambridge 347
Nyköping 338
Rome 316
Lauterbourg 275
Houston 270
Dallas 265
Woodbridge 265
Seattle 262
Bari 254
New York 237
Wilmington 231
Chandler 224
Lawrence 222
Ho Chi Minh City 213
Roxbury 202
Los Angeles 201
Jakarta 178
Santa Clara 172
Beijing 157
São Paulo 147
Paris 141
Chicago 139
Hanoi 129
Boardman 122
Des Moines 122
Falkenstein 122
Columbus 117
Ann Arbor 112
Dong Ket 111
Buffalo 99
San Diego 91
Phoenix 82
Nuremberg 78
Inglewood 75
London 74
Figino 68
Salt Lake City 67
Rio de Janeiro 55
North Bergen 54
Brooklyn 53
Frankfurt am Main 50
Toronto 50
Turin 50
Abidjan 47
Dublin 47
Montreal 47
Tokyo 44
Atlanta 41
Belo Horizonte 41
Munich 41
Naples 41
Guayaquil 39
San Francisco 37
Johannesburg 36
Orem 34
Tashkent 34
Vienna 34
Baghdad 33
Denver 31
Quito 31
Warsaw 31
Curitiba 30
Brasília 28
Manchester 28
Porto Alegre 28
Salvador 28
Da Nang 27
Medellín 27
San Salvador 27
Elk Grove Village 26
Haiphong 26
Istanbul 26
San José 26
Caracas 24
Florence 24
Chennai 23
Jeddah 23
Lahore 23
Buenos Aires 22
Kingston 22
Las Vegas 22
Managua 22
Mexico City 22
Philadelphia 22
Dhaka 21
Bogotá 20
Campinas 20
Washington 20
Guarulhos 19
Miami 19
Amman 18
Amsterdam 18
Totale 15.103
Salva come PNG Salva come JPEG
Nome #
SIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM) 322
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study 265
KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation 190
Management of targeted therapies in cancer patients with chronic kidney disease, or on haemodialysis: An Associazione Italiana di Oncologia Medica (AIOM)/Societa’ Italiana di Nefrologia (SIN) multidisciplinary consensus position paper 181
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 166
The ATM Gene in Breast Cancer: Its Relevance in Clinical Practice 159
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification 158
An update on Merkel cell carcinoma 157
The clonal heterogenicity of circulating tumor cells (CTCs) drives their metastatic potential: a new NOD‐SCID melanoma model 156
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial 153
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 149
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma 149
Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma 147
KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer 146
Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey 145
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial 141
Novel Insights into Autophagy and Prostate Cancer: A Comprehensive Review 140
Integration of lipidomics and transcriptomics reveals reprogramming of the lipid metabolism and composition in clear cell renal cell carcinoma 139
Algorithms in the first-line treatment of metastatic clear cell renal cell carcinoma—analysis using diagnostic nodes 136
Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma 135
Liquid Biopsy as a Tool Exploring in Real-Time Both Genomic Perturbation and Resistance to EGFR Antagonists in Colorectal Cancer 133
Large extracellular vesicles—a new frontier of liquid biopsy in oncology 133
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial 133
Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma 133
Massive hyper-progression during anti-PD1 immunotherapy in a young patient with metastatic mucinous adenocarcinoma of the right colon: a case report and literature review 132
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 130
Application of “omics” sciences to the prediction of bone metastases from breast cancer: State of the art 129
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up 128
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? 128
Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma 127
Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies 125
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 123
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 123
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 122
Prognostic factors and current treatment strategies for renal cell carcinoma metastatic to the brain: An overview 122
1101MO Development of CAR T-cells for future treatment of NETs 120
An anti-mica/b antibody and il-15 rescue altered nkg2d-dependent nk cell responses in hepatocellular carcinoma 119
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 118
Exploring the Spectrum of Kidney Ciliopathies 117
ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma 117
Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 116
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 114
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 114
An evaluation of UGN-101, a sustained-release hydrogel polymer-based formulation containing mitomycin-C, for the treatment of upper urothelial carcinomas 113
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy 112
Non-Melanoma Skin Cancers: Biological and Clinical Features 111
Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases 110
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 109
A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer 109
Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations 108
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: Study design and rationale 108
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study 107
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinoma 107
Hormone signaling pathways as treatment targets in renal cell cancer (Review) 107
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 106
Characterization of the metastatic behavior and gene expression profile (RNAseq) of different melanoma cell lines: a comprehensive in vivo model. 106
Beyond ras and braf: Her2, a new actionable oncotarget in advanced colorectal cancer 106
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand? 104
Metabolomic Approaches for Detection and Identification of Biomarkers and Altered Pathways in Bladder Cancer 104
Biliary tract cancers: moving from the present standards of care towards the use of immune checkpoint inhibitors 104
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists 102
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 102
Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis 102
The emerging role of PI3K inhibitors for solid tumour treatment and beyond 101
Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study 101
Primary soft tissue sarcoma of the heart: An emerging chapter in cardio-oncology 101
Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions 101
Adjuvant therapy in renal cell carcinoma 100
Understanding the mechanisms of resistance in EGFR-positive NSCLC: From tissue to liquid biopsy to guide treatment strategy 100
Choosing the right cell line for renal cell cancer research 99
Uterine carcinosarcoma: An overview 99
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association with Survival 99
Liquid biopsy in cervical cancer: Hopes and pitfalls 99
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: The RAINBOW analysis 98
Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial 98
A multiparametric approach to improve the prediction of response to immunotherapy in patients with metastatic NSCLC 98
Stereotactic ablative radiation therapy for renal cell carcinoma with inferior vena cava tumor thrombus 98
Acute Kidney Injury in Cancer Patients 97
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell Carcinoma 96
[Current approaches to the first-line treatment of clear-cell renal cell carcinoma] 96
Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study 96
An Italian, multicenter, real-world, retrospective study of first-line pazopanib in unselected metastatic renal-cell carcinoma patients: the 'Pamerit' study 96
Ongoing Clinical Trials and Future Research Scenarios of Circulating Tumor DNA for the Treatment of Metastatic Colorectal Cancer 95
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study 95
Opening an onconephrology clinic: Recommendations and basic requirements 95
Melanoma Brain Metastases: A Retrospective Analysis of Prognostic Factors and Efficacy of Multimodal Therapies 95
Nivolumab + ipilimumab (N+I) vs sunitinib (S) dans le traitement de première ligne du carcinome rénal avancé (aRCC) dans l’étude CheckMate 214 : suivi à 4 ans et analyse en sous-groupe des patients (pts) non néphrectomisés 94
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib 93
A Glimpse in the Future of Malignant Mesothelioma Treatment 93
Abstract 2012: In vitro validation of tumor-derived large extracellular vesicles isolation and characterization as suitable tool for liquid biopsy 91
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium 91
Mucosal Melanoma: Epidemiology, Clinical Features, and Treatment 90
MiT translocation renal cell carcinoma: A review of the literature from molecular characterization to clinical management 90
Development of extracellular matrix supported 3D culture of renal cancer cells and renal cancer stem cells 90
Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma 90
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: Results of the DATECAN project 89
Use of a natural multicomponent mouthwash plus oral hygiene vs oral hygiene alone to prevent everolimus-induced stomatitis: the STOP multicenter, randomized trial 89
Onco-nephrology: A decalogue 88
Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistance 88
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium 88
Totale 11.844
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.743
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.209 0 0 0 16 66 162 24 40 150 148 226 377
2022/20231.206 236 152 137 22 73 139 138 77 151 10 20 51
2023/2024716 46 240 48 40 54 110 22 39 38 11 13 55
2024/20254.713 207 27 493 256 83 331 473 235 259 370 730 1.249
2025/202612.138 1.294 467 832 1.437 815 622 1.247 611 1.446 1.206 472 1.689
2026/20273.772 648 685 802 1.637 0 0 0 0 0 0 0 0
Totale 26.652